drugset / Trial / NCT00593944
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see at what dose MDX-1342, a monoclonal antibody, is safe and tolerable for patients with chronic lymphocytic leukemia (CLL). Information on any responses that patients may have to the drug will also be collected.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MDX-1342 | Monoclonal antibody | 0.7 mg | Intravenous |
| Subject | MDX-1342 | Monoclonal antibody | 7 mg | Intravenous |
| Subject | MDX-1342 | Monoclonal antibody | 40 mg | Intravenous |
| Subject | MDX-1342 | Monoclonal antibody | 200 mg | Intravenous |
| Subject | MDX-1342 | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | MDX-1342 | Monoclonal antibody | 2000 mg | Intravenous |